UBS Raises Regeneron Pharmaceuticals (REGN) Price Target to $978

UBS has upgraded its rating on Regeneron Pharmaceuticals to Buy, setting a new target price of $978, a 22.83% upside from the current price.

By EarningsIQ Research Desk · Published Oct 15, 2026, 9:18 PM EDT · Updated Oct 16, 2026, 11:15 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

UBS raised its price target on Regeneron Pharmaceuticals, Inc. ($REGN) to $978 from $660 on October 15, 2026, and rates the stock "Buy".

Since the rating, $REGN is down 0.7% to date (from the $796.34 close on Oct 15, 2026).

REGN Regeneron Pharmaceuticals, Inc.

$790.74 +2.25% year to date

Daily close · Oct 16, 2026

Key Points

UBS raised its rating on Regeneron Pharmaceuticals, Inc. to Buy and set a price target of $978, up from $660.
UBS's $978 price target implies 22.83% upside from Regeneron Pharmaceuticals, Inc.'s ($REGN) current $796.21 share price.
Regeneron's shares recently traded around $796.21, which is about 18.6% below UBS's new target.
The company is set to report earnings on October 28, 2026, following a strong revenue growth of 16.7% year-over-year.

Get $REGN trade alerts by text

We text you when insiders, Congress or big funds trade $REGN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Regeneron Pharmaceuticals, Inc. alert may contain errors. Disclosures

UBS upgraded its rating on Regeneron Pharmaceuticals, Inc. (NasdaqGS: REGN) to Buy on October 15, 2026, raising its price target from $660 to $978. This reflects a notable increase in their outlook for the company. Regeneron’s shares were recently trading around $796.21, which is about 18.6% below the new target set by UBS.

Analyst rating track record

UBS vs. the S&P 500

YTD return -2.14% hypothetical

All-time return -2.14% S&P 500 +0.72%

vs. S&P 500 -2.86% behind the index

Hypothetical returns from UBS's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Regeneron Pharmaceuticals

Several other institutional investors have shown interest in Regeneron recently. Blackrock Inc. grew its holdings by 165,537 shares, ending with 9,113,506 shares worth about $7.21 billion. Dodge & Cox Inc. added 412,838 shares, bringing its total to 4,871,137 shares valued at approximately $3.85 billion. State Street Corporation also increased its stake by 170,252 shares, reaching a total of 4,834,688 shares valued at around $3.82 billion.

Regeneron Pharmaceuticals, Inc. Stock Holds Steady

Regeneron’s shares were trading at $796.21 as of October 16, 2026. This price is significantly below UBS's new target of $978, suggesting potential room for growth. The stock has been performing well, but this gap indicates that investors may see more upside if the target is reached.

12-month forecast

$REGN price target

Regeneron Pharmaceuticals, Inc. daily closes and this analyst's $978 target. Not advice.

Recent Earnings

Regeneron reported trailing twelve-month revenue of approximately $15.53 billion, with a net margin of 27.9% and a return on equity of 14.0%. The company has shown robust performance, with revenue growth of 16.7% year-over-year. It is scheduled to release its next earnings report on October 28, 2026.

Insider Buying and Selling at Regeneron Pharmaceuticals, Inc.

Recent insider transactions included several sales. On August 10, 2026, Director Huda Y Zoghbi sold 800 shares at a price of $800, totaling $640,000. Director Kathryn Ph.D. Guarini sold 400 shares at $850, amounting to $340,000 on September 2, 2026. Additionally, on October 14, 2026, Co-Chief Scientific Officer Andrew J. Murphy sold 4,147 shares at an average price of approximately $772.70, valued at around $3.20 million.

Analysts Set New Price Targets

On October 15, 2026, UBS upgraded its rating on Regeneron to Buy and set a target price of $978, up from a prior target of $660. Earlier, on October 6, JP Morgan maintained an Overweight rating with a target of $950, while Truist Securities and Morgan Stanley kept their ratings at Buy and Equal-Weight, respectively, with targets of $780 and $779.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers and develops medicines for various diseases, including cancer and rare conditions. The company is known for its innovative treatments and has a strong presence in the biotechnology sector. The recent analyst upgrade from UBS highlights growing confidence in its future potential.

Bottom Line

Investors will be watching for Regeneron's next earnings report on October 28, 2026, as well as any further updates from analysts after this upgrade. UBS's new price target suggests there may be significant upside potential for the stock if it can close the gap to the target.